P
Peter C. Taylor
Researcher at University of Oxford
Publications - 397
Citations - 19020
Peter C. Taylor is an academic researcher from University of Oxford. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 63, co-authored 359 publications receiving 16347 citations. Previous affiliations of Peter C. Taylor include HealthPartners & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Novel Candidate Genes in Unstable Areas of Human Atherosclerotic Plaques
Marianna Papaspyridonos,Alberto Smith,kevin Burnand,Peter C. Taylor,Soundrie Padayachee,Keith E. Suckling,Christian H. James,David R. Greaves,Lisa Patel +8 more
TL;DR: The differential expression of 18 genes not previously associated with plaque rupture has been confirmed in stable and unstable regions of the same atherosclerotic plaque, which may represent novel targets for the treatment of unstable plaque or useful diagnostic markers of plaque instability.
Journal ArticleDOI
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes
Myles Lewis,Michael R. Barnes,Michael R. Barnes,K. Blighe,Katriona Goldmann,Sharmila Rana,Jason A. Hackney,Nandhini Ramamoorthi,Christopher R. John,David Watson,David Watson,David Watson,Sarah K. Kummerfeld,Rebecca Hands,Sudeh Riahi,Vidalba Rocher-Ros,Felice Rivellese,Frances Humby,Stephen Kelly,Michele Bombardieri,Nora Ng,M DiCicco,Désirée van der Heijde,Robert Landewé,Annette H M van der Helm-van Mil,Alberto Cauli,Iain B. McInnes,Christopher D. Buckley,Christopher D. Buckley,Ernest Choy,Peter C. Taylor,Michael J. Townsend,Costantino Pitzalis +32 more
TL;DR: In this paper, a comprehensive RNA sequencing analysis of the molecular pathways that drive early RA progression in the disease tissue (synovium), comparing matched peripheral blood RNA-seq in a large cohort of early treatment-naive patients, namely, the Pathobiology of Early Arthritis Cohort (PEAC).
Journal ArticleDOI
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
Rene Westhovens,Peter C. Taylor,Rieke Alten,D. Pavlova,F. Enriquez-Sosa,Minodora Mazur,Maria Greenwald,A Van der Aa,Frédéric Vanhoutte,Chantal Tasset,P. Harrison +10 more
TL;DR: Filgotinib as add-on to MTX improved the signs and symptoms of active RA over 24 weeks and was associated with a rapid onset of action and dose-dependent responses.
Journal ArticleDOI
Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.
José María Álvaro-Gracia,Juan Angel Jover,Rosario García-Vicuña,Luis Carreño,Alberto Alonso,Sara Marsal,Francisco J. Blanco,Víctor M. Martínez-Taboada,Peter C. Taylor,Cristina Martín-Martín,Olga DelaRosa,Ignacio Tagarro,Federico Díaz-González +12 more
TL;DR: The intravenous infusion of Cx611 was in general well tolerated, without evidence of dose-related toxicity at the dose range and time period studied, and a trend for clinical efficacy was observed.
Journal ArticleDOI
Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
Ann-Kristin Ulfgren,Ulf Andersson,Marianne Engström,Lars Klareskog,Ravinder N. Maini,Peter C. Taylor +5 more
TL;DR: Analysis of synovial tissue by means of immunomorphology and image analysis in a clinical trial setting may allow the drawing of biologically meaningful conclusions.